GlassScriptPhysician profile
Michelle Gamazo
NPI 1952903247
$2,394.74
in general payments reported to CMS, 2019-2025
20 companies · $341 in 2025
The $341 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $300 · 2023: $1,261 · 2024: $493 · 2025: $341.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,095.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,094.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $246.93 | 2022-2023 | Monoferric |
| Astrazeneca Pharmaceuticals LP | $153.23 | 2023-2025 | Imfinzi, Enhertu |
| Daiichi Sankyo INC. | $150.56 | 2024-2025 | Enhertu |
| Dendreon Pharmaceuticals LLC | $145.38 | 2023 | Provenge |
| Beigene USA, INC. | $125.00 | 2023 | Brukinsa |
| Astellas Pharma US INC | $124.99 | 2024 | Xtandi |
| E.R. Squibb & Sons, L.L.C. | $124.81 | 2025 | Reblozyl |
| Regeneron Healthcare Solutions, INC. | $124.81 | 2023 | Libtayo |
| Amgen INC. | $124.81 | 2023 | Nplate |
| Seagen INC. | $124.50 | 2023 | Tivdak |
| Genmab U.S., INC. | $124.49 | 2023 | Epkinly |
| Eisai INC. | $123.19 | 2024 | |
| Abbvie INC. | $123.06 | 2024 | |
| Octapharma USA, INC. | $121.44 | 2023 | Wilate - Von Willebrand Factor/Coagulation Factor Viii Complex (Human) |
| Glaxosmithkline, LLC. | $114.66 | 2025 | Ojjaara |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $107.33 | 2022 | |
| Janssen Pharmaceuticals, INC | $95.91 | 2022 | |
| Genzyme Corporation | $95.76 | 2023 | |
| Janssen Biotech, INC. | $30.08 | 2025 | Darzalex, Tecvayli |
| Sumitomo Pharma America, INC. | $13.80 | 2025 | Gemtesa |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Gamazo listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.